Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures (Astax-ART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02310087|
Recruitment Status : Recruiting
First Posted : December 5, 2014
Last Update Posted : May 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|Infertility, Male||Dietary Supplement: astaxanthin with vitamin E Other: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Effect of Oral Administration of Astaxanthin on Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures|
|Study Start Date :||November 2014|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||December 2019|
Active Comparator: astaxanthin with vitamin E
The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
Dietary Supplement: astaxanthin with vitamin E
Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
Other Name: Astasan, Sensilab, Slovenia
Placebo Comparator: placebo
The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
Four tablets of placebo daily, taken at once. Continuously for three months.
- semen quality [ Time Frame: three months ]In semen quality the spermiogram, DNA fragmentation and mitochondrial membrane potential before and after the intervention will be evaluated. The DNA fragmentation will be evaluated by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) method, and mitochondrial membrane potential with carbocyanine fluorochrome DiOC6.
- follicle stimulating hormone (FSH) [ Time Frame: three months ]FSH levels in before and after the intervention will be evaluated in infertile men with oligoasthenozoospermia.
- fertilization and embryo development in Assisted Reproduction Techniques (ART) [ Time Frame: six months ]Fertilization rates and the quality of embryo development on day 3 in ICSI procedure in infertile couples will be determined after the three months of dietary supplementation of astaxanthin with vitamin E taken by infertile men with oligoasthenozoospermia.
- pregnancy rates and miscarriage rates in 1st trimester after ART [ Time Frame: nine months ]Pregnancy rates and miscarriage rates in 1st trimester after ART will be determined after the three months of dietary supplementation of astaxanthin with vitamin E taken by infertile men with oligoasthenozoospermia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02310087
|Contact: Bojana Pinter, MD, PhDfirstname.lastname@example.org|
|Contact: Senka Imamovic Kumalic, MDemail@example.com|
|Division of Ob/Gyn, University Medical Centre Ljubljana||Recruiting|
|Ljubljana, Slovenia, 1000|
|Contact: Bojana Pinter, MD, PhD +386-41-718-923 firstname.lastname@example.org|
|Contact: Senka Imamovic Kumalic, MD +386-40-614-904 email@example.com|
|Principal Investigator:||Bojana Pinter, MD, PhD||Division of Ob/Gyn, University Medical Centre Ljubljana, Slovenia|